Adverse drug reactions related to cytotoxic drugs: A pharmacovigilance in a comprehensive cancer institute;Effets indésirables des médicaments anticancéreux: À propos d'une étude de pharmacovigilance au sein d'une institution spécialisée en cancérologie

Therapie

Volumn 55, Issue 5, 2000, Pages 635-641

  Couffignal, A L ^a   Lapeyre Mestre, M ^a   Bonhomme, C ^b   Bugat, R ^b   Montastruc, J L ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Adverse drug reaction; Anti neoplastic drugs; Cost

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MESNA; METHOTREXATE; NAVELBINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CENTER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; COST OF ILLNESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITAL COST; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CASE MANAGEMENT; DATABASES, FACTUAL; DIAGNOSIS-RELATED GROUPS; DRUG UTILIZATION; FEMALE; FRANCE; HOSPITAL COSTS; HUMANS; INCIDENCE; INPATIENTS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0034536990     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Computerized surveillance of adverse drug events in hospital patients
2. Drug-related emergency department visits and hospital admissions
3. Incidence of adverse drug events and potential adverse drug events: Implication for prevention
4. Drug related morbidity and mortality
5. Hospitalisation for adverse events related to drug therapy: Incidence, avoidability and costs
6. Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality
7. Frequency and cost of serious adverse drug reactions in a department of general medicine
8. Incidence of adverse drag reactions in hospitalized patients. A meta-analysis of prospective studies
9. Iatrogénie médicamenteuse: Estimation de sa prévalence dans les hôpitaux publics francais
10. Evaluation of the cost of hospitalisations related to side effects of drugs
11. The costs of treating toxicities in cancer chemotherapy patients
12. Drug-related hospital admissions
13. Décret n° 95-278 du 13 mars 1995 relatif à la pharmacovigilance et modifiant le code de la santé publique
14. Use of a database computer program to identify trends in reporting of adverse drug reactions
15. Intensive hospital-based cohort studies
16. Computerized surveillance of adverse drug reactions in hospital: Pilot study
17. Systems analysis of adverse drug events
18. Adverse drug reactions: Comparison of two report methods
19. Incidence and cost of adverse drug reactions in a French cancer institute
20. L'outil PMSI: Biais, sources d'erreurs et conséquences
21. Evaluation de la qualité de l'information medicale des résumés de sortie standardisés
22. Current guidelines on the use of antibacterial drugs in patients with malignancies
23. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients
24. Economic study of neutropenia induced by myelotoxic chemotherapy
25. Pharmacoeconomic aspects in the treatment of curable and incurable cancer
26. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer
27. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence based clinical practice guidelines
28. Indirect drug-related costs
29. The costs of adverse drug events in hospitalized patients
30. Impact économique des effets indésirables des médicaments: Quelques réflexions
31. Analyse en coūt reel des activités soignantes d'un service de radiothérapie
32. Prévalence des trente affections de longue durée pour les affiliés an régime général de l'Assurance Maladie en 1994
33. Clinical impact of chemotherapy dose escalation